“…A previous study revealed that lncRNA miR503HG was downregulated in OC, and downregulation of miR503HG predicted poor survival of OC patients (Zhu et al, 2020 ), which coincided with miR503HG in our prognostic risk model signature. Coincidentally, the expression of MIR503HG was decreased in colon cancer (Chuo et al, 2019 ; Han H. et al, 2020 ), triple-negative breast cancer (Fu et al, 2019 ; Tuluhong et al, 2020 ), non-small cell lung cancer (Lin et al, 2019 ; Dao et al, 2020 ; Xu et al, 2020 ), cervical squamous cell carcinoma (Zhao et al, 2020 ), bladder cancer (Qiu et al, 2019 ), and hepatocellular carcinoma (Wang et al, 2018 ). MIR503HG was also proved to serve as a tumor suppressor in in vivo experiment.…”